
FDA Sends CRL for PET Imaging Agent in Progressive/Recurrent Glioma
The FDA has issued a complete response letter (CRL) for TLX101-CDx (18F-floretyrosine; 18F-FET; Pixclara), a PET agent designed for the characterization of progressive or recurrent glioma in adult and pediatric patients, according to a press release from …